Ramatroban (KAR101)

About KARE Biosciences

KARE Biosciences is a private, pre-revenue biotech focused on drug repurposing and supplement development. Its core asset is ramatroban (KAR101), a repurposed thromboxane A2 receptor antagonist, which is in a Phase 2/3 trial for COVID-19 pneumonia and is being explored preclinically for sickle cell disease, cardiovascular, neurological, and metabolic disorders. The company operates with a lean model, leveraging existing drug safety data to potentially accelerate development in areas with high unmet need, though it faces significant risks related to clinical validation, competition, and funding.

About KARE Biosciences

KARE Biosciences is a private, pre-revenue biotech focused on drug repurposing and supplement development. Its core asset is ramatroban (KAR101), a repurposed thromboxane A2 receptor antagonist, which is in a Phase 2/3 trial for COVID-19 pneumonia and is being explored preclinically for sickle cell disease, cardiovascular, neurological, and metabolic disorders. The company operates with a lean model, leveraging existing drug safety data to potentially accelerate development in areas with high unmet need, though it faces significant risks related to clinical validation, competition, and funding.

About KARE Biosciences

KARE Biosciences is a private, pre-revenue biotech focused on drug repurposing and supplement development. Its core asset is ramatroban (KAR101), a repurposed thromboxane A2 receptor antagonist, which is in a Phase 2/3 trial for COVID-19 pneumonia and is being explored preclinically for sickle cell disease, cardiovascular, neurological, and metabolic disorders. The company operates with a lean model, leveraging existing drug safety data to potentially accelerate development in areas with high unmet need, though it faces significant risks related to clinical validation, competition, and funding.

About KARE Biosciences

KARE Biosciences is a private, pre-revenue biotech focused on drug repurposing and supplement development. Its core asset is ramatroban (KAR101), a repurposed thromboxane A2 receptor antagonist, which is in a Phase 2/3 trial for COVID-19 pneumonia and is being explored preclinically for sickle cell disease, cardiovascular, neurological, and metabolic disorders. The company operates with a lean model, leveraging existing drug safety data to potentially accelerate development in areas with high unmet need, though it faces significant risks related to clinical validation, competition, and funding.

About KARE Biosciences

KARE Biosciences is a private, pre-revenue biotech focused on drug repurposing and supplement development. Its core asset is ramatroban (KAR101), a repurposed thromboxane A2 receptor antagonist, which is in a Phase 2/3 trial for COVID-19 pneumonia and is being explored preclinically for sickle cell disease, cardiovascular, neurological, and metabolic disorders. The company operates with a lean model, leveraging existing drug safety data to potentially accelerate development in areas with high unmet need, though it faces significant risks related to clinical validation, competition, and funding.

About KARE Biosciences

KARE Biosciences is a private, pre-revenue biotech focused on drug repurposing and supplement development. Its core asset is ramatroban (KAR101), a repurposed thromboxane A2 receptor antagonist, which is in a Phase 2/3 trial for COVID-19 pneumonia and is being explored preclinically for sickle cell disease, cardiovascular, neurological, and metabolic disorders. The company operates with a lean model, leveraging existing drug safety data to potentially accelerate development in areas with high unmet need, though it faces significant risks related to clinical validation, competition, and funding.

About KARE Biosciences

KARE Biosciences is a private, pre-revenue biotech focused on drug repurposing and supplement development. Its core asset is ramatroban (KAR101), a repurposed thromboxane A2 receptor antagonist, which is in a Phase 2/3 trial for COVID-19 pneumonia and is being explored preclinically for sickle cell disease, cardiovascular, neurological, and metabolic disorders. The company operates with a lean model, leveraging existing drug safety data to potentially accelerate development in areas with high unmet need, though it faces significant risks related to clinical validation, competition, and funding.

Therapeutic Areas